GENE ONLINE|News &
CDSCO Approves Durvalumab with FLOT Chemotherapy for Perioperative Treatment of Resectable Gastric and GEJ Cancer in India
The Central Drugs Standard Control Organisation (CDSCO) has approved the use of durvalumab in combination with FLOT chemotherapy for the treatment of resectable gastric and gastroesophageal junction (GEJ) cancer in India. This decision is based on findings from the Phase III MATTERHORN study, which evaluated the perioperative use of this combination therapy.
The MATTERHORN study provided evidence supporting the efficacy and safety of combining durvalumab, an immunotherapy drug, with FLOT, a standard chemotherapy regimen consisting of fluorouracil, leucovorin, oxaliplatin, and docetaxel. The approval allows this treatment to be used during the perioperative period for patients diagnosed with resectable forms of gastric and GEJ cancers. This marks a significant regulatory development aimed at expanding therapeutic options for these types of cancers in India.
Newsflash | Powered by GeneOnline AI
Source: GO-AI-ne1
For any suggestion and feedback, please contact us.
Date: February 4, 2026
©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Author
LATEST
Applied Materials Resolves U.S. Export Control Investigation with Financial Penalty and Compliance Measures
2026-02-11
Sands China Partners with Alipay and Macau Pass to Expand Cashless Payment Systems in Macau
2026-02-11
Beach Cities Commercial Bank Reports $12.4 Million Q4 Net Income with $2.1 Billion in Total Assets
2026-02-11
